Nuvisan Pharma Services, a CRO/CDMO group specialized in drug development services, has acquired Inamed GmbH, an international CRO specialized in respiratory and rare diseases clinical trials.

This acquisition gives Nuvisan access to patient populations that are difficult to recruit, such as patients with cystic fibrosis. Inamed offers orally inhaled products flow-profile studies along with technical preparation of devices, flow-profile measurements, in-house clinical performance and management...